SCHEDULE: Vanguard Discloses 5.05% Stake in Ionis Pharmaceuticals

Vanguard Capital Management has reported beneficial ownership of over 8.3 million shares, representing 5.05% of Ionis Pharmaceuticals' common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, has filed a Schedule 13G indicating beneficial ownership of 8,344,732 shares of Ionis Pharmaceuticals' common stock.
• This holding represents 5.05% of the total class of securities.
• The filing is made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934.
• Vanguard Capital Management exercises sole dispositive power over these shares and has sole voting power over 1,226,402 shares.
• The filing reflects securities held by Vanguard funds and other managed accounts where Vanguard exercises dispositive and/or voting power.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, as it indicates significant institutional confidence from a major asset manager like Vanguard, though it does not provide direct operational or financial updates from the company itself.

Positives

• Vanguard's significant stake suggests confidence in Ionis Pharmaceuticals' long-term prospects.
• The filing indicates that Vanguard funds and managed accounts have the right to receive dividends and proceeds from the sale of these securities, implying potential income generation for these entities.

Negatives

• The filing does not contain any negative financial performance indicators or operational challenges for Ionis Pharmaceuticals.

Risks

• The filing does not explicitly mention any risks associated with Ionis Pharmaceuticals' business operations or the investment itself.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Ionis Pharmaceuticals. It solely reports Vanguard's investment position.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that a significant institutional investor like Vanguard taking a stake of over 5% in a biotechnology company like Ionis Pharmaceuticals often signals a positive outlook on the company's drug pipeline and commercialization strategies within the competitive biopharmaceutical sector.

Stakeholder Impact

• Shareholders: The filing may be viewed positively by existing shareholders as it signals institutional confidence, potentially supporting share price stability or appreciation.
• Vanguard Investors: Investors in Vanguard funds that hold Ionis Pharmaceuticals stock will benefit from any positive performance of the company.

Next Steps

• Vanguard will continue to monitor its investment in Ionis Pharmaceuticals.
• Ionis Pharmaceuticals will continue its operations and drug development activities.

Key Dates

Recommendation

This filing is a Schedule 13G, indicating a passive investment stake by Vanguard. It does not provide new operational or financial performance data from Ionis Pharmaceuticals itself. While Vanguard's investment is a positive signal of institutional confidence, it does not offer sufficient new information to warrant a change from a 'hold' recommendation without further analysis of Ionis Pharmaceuticals' core business performance.

Keywords

Ionis Pharmaceuticals, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Pharmaceuticals